Shares in the biotech company gained 19.33% to $1.42 each.
The data will be given in what's called a poster presentation in the Netherlands.
The study investigated the effect of OCR-002 in a rat with the disease in which animals were fed a High Fat and High Cholesterol (HFHC) diet for up to 16 weeks.
NAFLD rats treated with OCR-002 showed significant reduction in the progression of fibrosis compared to untreated NAFLD animals and OCR-002 substantially reduced the liver/body weight ratio, the hepatic lipid content, and hepatic collagen.
“We are again excited to see evidence of OCR-002’s ability to target ammonia in hyperammonemia-related indications that in turn drives clinical improvement,” said Stan Bukofzer, Ocera’s chief medical officer.